Literature DB >> 7019327

In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor.

M Rosenstein, T Eberlein, M M Kemeny, P H Sugarbaker, S A Rosenberg.   

Abstract

The ability of adoptively transferred cytotoxic T cells expanded in T cell growth factor (TCGF) to induce accelerated graft rejection of B10.BR skin grafts from normal B6AF1 recipient mice was tested. In vitro sensitized cells expanded in regular TCGF were capable of accelerating graft rejection when adoptively transferred i.v. 1 day after grafting. Cells expanded in LF-TCGF (lectin-free) were more effective in accelerating graft rejection than cells expanded in lectin containing TCGF. Nonsensitized cells or cells sensitized to irrelevant B10.D2 antigenic determinants in vitro and subsequently expanded in LF-TCGF were unable to induce accelerated rejection of the B10.BR grafts. Expanded cytotoxic effector cells known to be immunologically active in vivo were also unable to accelerate graft rejection if irradiated with 2000 R before adoptive transfer. The ability of cells to lyse the appropriate targets in 4-hr 51Cr release assays correlated poorly with the effectiveness of these cells after in vivo injection. These studies are the first to demonstrate that cytotoxic cells expanded in TCGF are capable of mediating a cytotoxic function in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7019327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

2.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

3.  The effect of cimetidine on PBL from healthy donors and melanoma patients: augmentation of T cell responses to TCGF mitogens and alloantigens and of TCGF production.

Authors:  A Eisenthal; J Monselise; R Zinger; A Adler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids.

Authors:  A M Nouri; G S Panayi; S M Goodman
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330

5.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Immersion in the search for effective cancer immunotherapies.

Authors:  Steven A Rosenberg
Journal:  Mol Med       Date:  2021-06-16       Impact factor: 6.354

7.  Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2.

Authors:  T J Eberlein; M Rosenstein; S A Rosenberg
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

Review 8.  Harnessing the immune system in the battle against breast cancer.

Authors:  Elizabeth S Nakasone; Sara A Hurvitz; Kelly E McCann
Journal:  Drugs Context       Date:  2018-02-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.